# Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer

> **NCT02690480** · PHASE2 · UNKNOWN · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 189 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** PD-0332991 (Palbociclib)
- **DRUG:** Fulvestrant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02690480
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-02-17
- **Primary completion:** 2020-01-11
- **Final completion:** 2023-12
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02690480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02690480, "Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02690480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*